Abstract Body

Background:

HIV integrase strand transfer inhibitors (InSTI) are popular among people living with HIV for their tolerability and low pill burden. However, compared to older antiretrovirals (ARVs), little is known about their mitochondrial toxicities. Dolutegravir has been associated with weight gain in adults, which may reflect changes in cellular metabolism regulated by mitochondria. Mitochondrial toxicity of more recently approved InSTIs bictegravir, elvitegravir+cobicistat, and cabotegravir remains unclear. We herein characterized the effects of InSTI exposure on cultured immune cell mitochondrial health, and proliferation.

Methods:

PBMCs from healthy volunteers were treated with T cell activator anti-CD3/CD28 for 6 days while also exposed to 1xCmax InSTIs in medium + 0.1% DMSO (ARV diluent). Mitochondrial intermembrane potential (MMP), reactive oxygen species (mtROS), and mass (mtmass), along with cellular proliferation and apoptosis, were determined by flow cytometry. Comparisons with the DMSO-exposed control cells were done by paired t-test. Additional experiments were performed to further explore changes in T-cell activation markers and T-cell memory compartments when exposed to InSTIs. These were carried out as above, with new antibodies for activation and differentiation.

Results:

Compared to DMSO controls (n=9 biological replicates), bictegravir exposure exerted the most pronounced effects, with two-fold decreased mtmass, mtROS, MMP, a five-fold decrease in proliferation, and one-fold increase in apoptosis, while elvitegravir+cobicistat decreased MMP and proliferation two-fold (all p< 0.001). In contrast, dolutegravir and cabotegravir both increased MMP by half-fold (p ≤0.045), while first generation InSTI raltegravir had no effect on these parameters. In preliminary experiments (n=3), exposure to some InSTIs appeared to decrease the relative proportion of CD4 central memory cells and/or increase expression of early activation marker when compared to DMSO controls.

Conclusions:

These data clearly show that some second generation InSTIs can affect mitochondria in cultured PBMCs. Furthermore, the effects of bictegravir ex vivo suggest a potential underlying metabolic mechanism which could hinder immune responses. Further exploration of the effect of InSTIs on T-cell activation is required as these types of toxicities may not be revealed by clinical trials yet could exert long-term immunological and health consequences.